文献速递冠心病心力衰竭与心肌病

严重缺血性心肌病:CABG与PCI长期生存比较

Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival.
PubMed 文献 · Eur Heart J · 2025-01-01

本研究基于澳大利亚和新西兰多中心注册数据,纳入2005至2018年接受血运重建的严重缺血性心肌病(LVEF<35%)患者2042例,比较CABG与PCI的长期生存。

要点

  • 严重缺血性心肌病患者中,CABG较PCI与更低的长期死亡率相关。
  • CABG围术期卒中风险显著高于PCI,需权衡获益与风险。
  • 该研究为非随机注册分析,结论需随机对照试验验证。

核心结论

  • 在多中心IPTW分析中,严重缺血性心肌病患者接受CABG而非PCI血运重建与更好的长期生存相关。

研究设计与样本

  • 基于澳大利亚和新西兰心脏与胸外科医师学会及墨尔本介入组注册研究,纳入2005年1月至2018年接受PCI或孤立CABG的严重缺血性心肌病(LVEF<35%)患者,排除ST段抬高型心肌梗死和心源性休克者,共2042例(CABG 1451例,PCI 591例)。
  • 采用倾向性评分逆概率治疗加权(IPTW)进行风险调整,评估平均治疗效应。

临床怎么用

  • 对于严重缺血性心肌病(LVEF<35%)需血运重建的患者,CABG可能带来长期生存获益,但应充分评估围术期卒中风险和住院时间延长的代价。

局限性

  • 研究为非随机注册分析,存在未测量混杂可能,需未来随机对照试验确认获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The optimal revascularization strategy in patients with ischaemic cardiomyopathy remains unclear with no contemporary randomized trial data to guide clinical practice. This study aims to assess long-term survival in patients with severe ischaemic cardiomyopathy revascularized by either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). METHODS: Using the Australian and New Zealand Society of Cardiac and Thoracic Surgeons and Melbourne Interventional Group registries (from January 2005 to 2018), patients with severe ischaemic cardiomyopathy [left ventricular ejection fraction (LVEF) <35%] undergoing PCI or isolated CABG were included in the analysis. Those with ST-elevation myocardial infarction and cardiogenic shock were excluded. The primary outcome was long-term National Death Index-linked mortality up to 10 years following revascularization. Risk adjustment was performed to estimate the average treatment effect using propensity score analysis with inverse probability of treatment weighting (IPTW). RESULTS: A total of 2042 patients were included, of whom 1451 patients were treated by CABG and 591 by PCI. Inverse probability of treatment weighting-adjusted demographics, procedural indication, coronary artery disease extent, and LVEF were well balanced between the two patient groups. After risk adjustment, patients treated by CABG compared with those treated by PCI experienced reduced long-term mortality [adjusted hazard ratio 0.59, 95% confidence interval (CI) 0.45-0.79, P = .001] over a median follow-up period of 4.0 (inter-quartile range 2.2-6.8) years. There was no difference between the groups in terms of in-hospital mortality [adjusted odds ratio (aOR) 1.42, 95% CI 0.41-4.96, P = .58], but there was an increased risk of peri-procedural stroke (aOR 19.6, 95% CI 4.21-91.6, P < .001) and increased length of hospital stay (exponentiated coefficient 3.58, 95% CI 3.00-4.28, P < .001) in patients treated with CABG. CONCLUSIONS: In this multi-centre IPTW analysis, patients with severe ischaemic cardiomyopathy undergoing revascularization by CABG rather than PCI showed improved long-term survival. However, future randomized controlled trials are needed to confirm the effect of any such benefits.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Bloom, Vogrin, Reid, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival. Eur Heart J. 2025. PMID: 39471463. doi:10.1093/eurheartj/ehae672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。